CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Clinical trials for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) explained in plain language.
Never miss a new study
Get alerted when new CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) trials appear
Sign up with your email to follow new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug JTE-162 aims to tame rare fever disorder
Disease control Recruiting nowThis early-phase study tests a new oral drug called JTE-162 in 5 adults with CAPS, a rare genetic condition causing fever, rash, and joint pain. Participants take the drug once daily for 2 weeks to see if it reduces inflammation and symptoms. The goal is to check safety and how w…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Phase: PHASE1 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New study tracks ilaris for rare fever diseases in kids and adults
Disease control Recruiting nowThis study watches how well the drug Ilaris works and how safe it is for children and adults with rare hereditary fever syndromes (like CAPS, FMF, TRAPS, HIDS/MKD) and a type of childhood arthritis called sJIA. About 25 people will be followed during their regular treatment. The …
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:13 UTC